| Activating Compound | Comment | Organism | Structure |
|---|---|---|---|
| lipopolysaccharide | activation by intracellular LPS leading to caspase-11 oligomerizes into protein complexes and enzymatic cleavage of gasdermin D (GSDMD) into pore-forming peptides. Recognition of LPS by caspase-11 requires guanylate-binding proteins (GBPs). LPS-caspase-11 interaction in the intestinal epithelium is not observed when GBPchr3 KO (knockout) mice, which lack GBP1, 2, 3, 5, and 7, are used as HSCT recipients | Mus musculus |
| Protein Variants | Comment | Organism |
|---|---|---|
| additional information | lipopolysaccharide (LPS)-caspase-11 interaction enhances graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Caspase-11 enhances donor T cell expansion in allo-HSCT | Mus musculus |
| Localization | Comment | Organism | GeneOntology No. | Textmining |
|---|---|---|---|---|
| cytosol | - |
Mus musculus | 5829 | - |
| Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| gasdermin D + H2O | Mus musculus | cleavage of gasdermin D (GSDMD) into pore-forming peptides | ? | - |
? |
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Mus musculus | P70343 | cf. caspase-4, EC 3.4.22.57; C57BL/6 and and BALB/c mice | - |
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| epithelium | - |
Mus musculus | - |
| intestine | - |
Mus musculus | - |
| lymphocyte | intraepithelial lymphocytes, and intestinal lamia propria lymphocytes | Mus musculus | - |
| macrophage | - |
Mus musculus | - |
| neutrophil | - |
Mus musculus | - |
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| gasdermin D + H2O | cleavage of gasdermin D (GSDMD) into pore-forming peptides | Mus musculus | ? | - |
? |
| Synonyms | Comment | Organism |
|---|---|---|
| caspase-11 | - |
Mus musculus |
| General Information | Comment | Organism |
|---|---|---|
| malfunction | deletion of caspase-11 or Gsdmd, inhibition of LPS-caspase-11 interaction, or neutralizing IL-1alpha uniformly reduces intestinal inflammation, tissue damage, donor T cell expansion, and mortality in allo-HSCT. Importantly, Caspase-11 deficiency does not decrease the graft-versus-leukemia (GVL) activity, which is essential to prevent cancer relapse. Caspase-11 deficiency preserves GVL activity, overview. Loss of caspase-11 renders mice susceptible to Burkholderia pseudomallei, a Gram-negative bacterium. Neutralizing IL-1alpha attenuates GVHD. Overactivation of caspase-11 in endotoxemia or polymicrobial sepsis leads to organ injury and lethality. Dysregulated activation of caspase-11 also contributes to the pathogenesis of age-related macular degeneration | Mus musculus |
| metabolism | caspase-11 is a cytosolic LPS receptor that senses various Gram-negative bacteria infections. Caspase-11 enhances GVHD through gasdermin D (GSDMD). GSDMD is a caspase-11 substrate that directly triggers pyroptosis | Mus musculus |
| physiological function | caspase-11 is a cytosolic LPS receptor that senses various Gram-negative bacteria infections. Caspase-11 is the cytosolic receptor for bacterial endotoxin (lipopolysaccharide, LPS). Caspase-11 signaling enhances graft-versus-host disease (GVHD). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) markedly increases the LPS-caspase-11 interaction, leading to the cleavage of gasdermin D (GSDMD). Caspase-11 and GSDMD mediate the release of interleukin-1alpha (IL-1alpha) in allo-HSCT. Upon activation by intracellular LPS, caspase-11 oligomerizes into protein complexes and enzymatically cleaves gasdermin D (GSDMD) into pore-forming peptides, leading to a lytic form of cell death, termed pyroptosis. This process destroys the intracellular niche for microbes and triggers inflammation by releasing alarmins, such as IL-1alpha | Mus musculus |